A novel nanocarrier sirolimus-coated balloon for coronary interventions: 12-Month data from the Nanoluté Registry

Sameer Dani, Dinesh Shah, Prakash Sojitra, Keyur Parikh, Ranjan Shetty, Gaetano di Palma, Bernardo Cortese

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: The aim of the Nanoluté registry was to observe the clinical performance of a novel sirolimus coated balloon (SCB) (Concept Medical Research Private Limited, India) for the treatment of coronary de-novo and restenotic lesions. Methods: All patients treated with SCB between July 2012 and September 2015 were enrolled at Indian centres and clinically followed for 1, 3, 6 and 12 months post-procedure. Primary endpoints were procedural success and device-oriented adverse cardiac events (DOCE) at 12 months. DOCE were defined as a composite of cardiac death, target lesion revascularization (TLR) and target vessel-myocardial infarction. Results: A total of 394 SCB were used in 332 patients to treat 356 lesions. In-stent restenosis and small coronary vessel disease occurred in 46% and 43% of the patients respectively. Mean balloon length and diameter (average ± SD) were 21.83 ± 6.70 mm and 2.69 ± 0.45 mm respectively. All patients with 1 year follow-up were included. Overall DOCE rate was 4.2% (n = 14) which included death 0.3% (n = 1), TLR 3.6% (n = 12) and myocardial infarction 0.3% (n = 1). Conclusion: The Nanoluté prospective registry, is the first clinical evidence of the safety and feasibility of this type of SCB, both in patients with in-stent restenosis or de novo lesions.

Original languageEnglish
Pages (from-to)235-240
Number of pages6
JournalCardiovascular Revascularization Medicine
Volume20
Issue number3
DOIs
Publication statusPublished - 01-03-2019
Externally publishedYes

Fingerprint

Sirolimus
Registries
Equipment and Supplies
Stents
Myocardial Infarction
Coronary Disease
Biomedical Research
India
Coronary Vessels
Safety

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Dani, Sameer ; Shah, Dinesh ; Sojitra, Prakash ; Parikh, Keyur ; Shetty, Ranjan ; di Palma, Gaetano ; Cortese, Bernardo. / A novel nanocarrier sirolimus-coated balloon for coronary interventions : 12-Month data from the Nanoluté Registry. In: Cardiovascular Revascularization Medicine. 2019 ; Vol. 20, No. 3. pp. 235-240.
@article{2e510c1d42d945328fd75b5dd974095a,
title = "A novel nanocarrier sirolimus-coated balloon for coronary interventions: 12-Month data from the Nanolut{\'e} Registry",
abstract = "Background: The aim of the Nanolut{\'e} registry was to observe the clinical performance of a novel sirolimus coated balloon (SCB) (Concept Medical Research Private Limited, India) for the treatment of coronary de-novo and restenotic lesions. Methods: All patients treated with SCB between July 2012 and September 2015 were enrolled at Indian centres and clinically followed for 1, 3, 6 and 12 months post-procedure. Primary endpoints were procedural success and device-oriented adverse cardiac events (DOCE) at 12 months. DOCE were defined as a composite of cardiac death, target lesion revascularization (TLR) and target vessel-myocardial infarction. Results: A total of 394 SCB were used in 332 patients to treat 356 lesions. In-stent restenosis and small coronary vessel disease occurred in 46{\%} and 43{\%} of the patients respectively. Mean balloon length and diameter (average ± SD) were 21.83 ± 6.70 mm and 2.69 ± 0.45 mm respectively. All patients with 1 year follow-up were included. Overall DOCE rate was 4.2{\%} (n = 14) which included death 0.3{\%} (n = 1), TLR 3.6{\%} (n = 12) and myocardial infarction 0.3{\%} (n = 1). Conclusion: The Nanolut{\'e} prospective registry, is the first clinical evidence of the safety and feasibility of this type of SCB, both in patients with in-stent restenosis or de novo lesions.",
author = "Sameer Dani and Dinesh Shah and Prakash Sojitra and Keyur Parikh and Ranjan Shetty and {di Palma}, Gaetano and Bernardo Cortese",
year = "2019",
month = "3",
day = "1",
doi = "10.1016/j.carrev.2018.06.003",
language = "English",
volume = "20",
pages = "235--240",
journal = "Cardiovascular Revascularization Medicine",
issn = "1553-8389",
publisher = "Elsevier Inc.",
number = "3",

}

A novel nanocarrier sirolimus-coated balloon for coronary interventions : 12-Month data from the Nanoluté Registry. / Dani, Sameer; Shah, Dinesh; Sojitra, Prakash; Parikh, Keyur; Shetty, Ranjan; di Palma, Gaetano; Cortese, Bernardo.

In: Cardiovascular Revascularization Medicine, Vol. 20, No. 3, 01.03.2019, p. 235-240.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A novel nanocarrier sirolimus-coated balloon for coronary interventions

T2 - 12-Month data from the Nanoluté Registry

AU - Dani, Sameer

AU - Shah, Dinesh

AU - Sojitra, Prakash

AU - Parikh, Keyur

AU - Shetty, Ranjan

AU - di Palma, Gaetano

AU - Cortese, Bernardo

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Background: The aim of the Nanoluté registry was to observe the clinical performance of a novel sirolimus coated balloon (SCB) (Concept Medical Research Private Limited, India) for the treatment of coronary de-novo and restenotic lesions. Methods: All patients treated with SCB between July 2012 and September 2015 were enrolled at Indian centres and clinically followed for 1, 3, 6 and 12 months post-procedure. Primary endpoints were procedural success and device-oriented adverse cardiac events (DOCE) at 12 months. DOCE were defined as a composite of cardiac death, target lesion revascularization (TLR) and target vessel-myocardial infarction. Results: A total of 394 SCB were used in 332 patients to treat 356 lesions. In-stent restenosis and small coronary vessel disease occurred in 46% and 43% of the patients respectively. Mean balloon length and diameter (average ± SD) were 21.83 ± 6.70 mm and 2.69 ± 0.45 mm respectively. All patients with 1 year follow-up were included. Overall DOCE rate was 4.2% (n = 14) which included death 0.3% (n = 1), TLR 3.6% (n = 12) and myocardial infarction 0.3% (n = 1). Conclusion: The Nanoluté prospective registry, is the first clinical evidence of the safety and feasibility of this type of SCB, both in patients with in-stent restenosis or de novo lesions.

AB - Background: The aim of the Nanoluté registry was to observe the clinical performance of a novel sirolimus coated balloon (SCB) (Concept Medical Research Private Limited, India) for the treatment of coronary de-novo and restenotic lesions. Methods: All patients treated with SCB between July 2012 and September 2015 were enrolled at Indian centres and clinically followed for 1, 3, 6 and 12 months post-procedure. Primary endpoints were procedural success and device-oriented adverse cardiac events (DOCE) at 12 months. DOCE were defined as a composite of cardiac death, target lesion revascularization (TLR) and target vessel-myocardial infarction. Results: A total of 394 SCB were used in 332 patients to treat 356 lesions. In-stent restenosis and small coronary vessel disease occurred in 46% and 43% of the patients respectively. Mean balloon length and diameter (average ± SD) were 21.83 ± 6.70 mm and 2.69 ± 0.45 mm respectively. All patients with 1 year follow-up were included. Overall DOCE rate was 4.2% (n = 14) which included death 0.3% (n = 1), TLR 3.6% (n = 12) and myocardial infarction 0.3% (n = 1). Conclusion: The Nanoluté prospective registry, is the first clinical evidence of the safety and feasibility of this type of SCB, both in patients with in-stent restenosis or de novo lesions.

UR - http://www.scopus.com/inward/record.url?scp=85052809294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052809294&partnerID=8YFLogxK

U2 - 10.1016/j.carrev.2018.06.003

DO - 10.1016/j.carrev.2018.06.003

M3 - Article

C2 - 30196029

AN - SCOPUS:85052809294

VL - 20

SP - 235

EP - 240

JO - Cardiovascular Revascularization Medicine

JF - Cardiovascular Revascularization Medicine

SN - 1553-8389

IS - 3

ER -